Clinical trials · New York
Triple Negative Breast Cancer clinical trials in New York
We’re tracking 62 recruiting triple negative breast cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT02977468RecruitingPhase 1
Pembrolizumab for early triple-negative breast cancer tumor changes
This Phase 1 study tests pembrolizumab (an immune medicine) to see how it affects the tumor and its surroundings in triple-negative breast cancer. It’s mainly looking at safety and early signs of benefit, especially in a limited, early-stage breast tumor.
New York, New YorkAges 21–80 - NCT02926690RecruitingPhase 1
MELK inhibitor safety study for advanced breast cancer
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
New York, New YorkAges 18 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
New York, New YorkAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Lake Success, New YorkAges 18 years+ - NCT07612215RecruitingPhase 1/Phase 2
Elacestrant for Advanced Triple-Positive Breast Cancer
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
New York, New YorkAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
New York, New YorkAges 18 years+ - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
New York, New YorkAges 18 years+ - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
Brooklyn, New YorkAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
New York, New YorkAges 18 years+ - NCT06400472RecruitingPhase 1
Study of LY4170156 for advanced solid tumors
This study tests a new drug called LY4170156 for people with certain advanced solid tumors. It aims to see if the drug is safe and how well it works.
New York, New YorkAges 18 years+ - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
New York, New YorkAges 18 years+ - NCT07339176RecruitingPhase 1/Phase 2
A trial of N17350 injected into tumors for advanced solid cancers
This trial tests an experimental drug, N17350, that is injected directly into tumors. It is for people with advanced solid tumors that have stopped responding to standard treatments or who cannot receive them. The study aims to see if this approach is safe and effective.
Buffalo, New YorkAges 18 years+ - NCT04969835RecruitingPhase 1
Safety and early response study of AVA6000 for solid tumors
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
New York, New YorkAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
New York, New YorkAges 18 years+
Triple Negative Breast Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting triple negative breast cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 6 studies
- NYU Langone Health · 3 studies
- Weill Cornell Medicine · 2 studies
- Columbia University Irving Medical Center
- Icahn School of Medicine at Mount Sinai
- Jamaica Hospital Medical Center
- Kings County Hospital Center
- Local Institution - 0002
What taking part in a triple negative breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Triple Negative Breast Cancer trials in other states
Common questions
- Are there triple negative breast cancer clinical trials in New York?
- Yes. We're currently tracking 62 recruiting triple negative breast cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a triple negative breast cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a triple negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New triple negative breast cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.